- GlobeNewswire•6 hours ago
EMERYVILLE, Calif., March 01, 2017-- Zogenix, Inc., a pharmaceutical company developing therapies for the treatment of orphan and central nervous system disorders, today announced that the European Commission ...
- GlobeNewswire•14 days ago
EMERYVILLE, Calif., Feb. 15, 2017-- Zogenix, Inc., a pharmaceutical company developing therapies for the treatment of orphan and central nervous system disorders, today announced that Michael P. Smith, ...
- GlobeNewswire•16 days agoZogenix Announces Initiation of Clinical Efficacy Portion of Study 1504 for ZX008 in Dravet Syndrome
Study 1504 Part of Phase 3 Program for ZX008 in Dravet Syndrome. Safety and Efficacy Portion of Study Expanded from EU to Include Sites in U.S. and Canada. EMERYVILLE, Calif., Feb. 13, 2017-- Zogenix, ...
ZGNX : Summary for Zogenix, Inc. - Yahoo Finance
Zogenix, Inc. (ZGNX)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
|Bid||10.30 x 800|
|Ask||10.35 x 300|
|Day's Range||10.25 - 10.55|
|52 Week Range||7.33 - 13.70|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-4.64|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|